Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.30 |
| ▸ | ABAT | P80404 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676434 | 0.70 | — | — | |
| SCHEMBL7537600 | 0.68 | — | — | |
| SCHEMBL346857 | 0.67 | — | — | |
| SCHEMBL152939 | 0.67 | — | — | |
| SCHEMBL1503787 | 0.65 | — | — | |
| SCHEMBL12422 | 0.65 | — | — | |
| SCHEMBL154878 | 0.65 | — | — | |
| SCHEMBL8226713 | 0.65 | — | — | |
| SCHEMBL4452150 | 0.65 | — | — | |
| SCHEMBL1244035 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-114835704-B | Sulfonylbenzamide derivatives as BCL-2 inhibitors | 苏州亚盛药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-113292540-B | N-fluorenyl benzocarbazole compound taking quinoxaline as auxiliary receptor, preparation method and application thereof | 浙江工业大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-113292540-A | N-fluorenyl benzocarbazole compound with quinoxaline as auxiliary receptor, preparation method and application thereof | 浙江工业大学 | 2021-08-24 | — | — | CN | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-5698574-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | KDM4E 3052/4885PTGS2 2422/4885RAB9A 1139/4885 |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | KDM4E 1780/4885PTGS2 1531/4885RAB9A 1036/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | KDM4E 2465/4885PTGS2 270/4885RAB9A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.